Navigation Links
Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
Date:6/17/2008

Demonstrating outstanding healthcare delivery practices and compliance

SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today their accreditation as an Exemplary Provider for Medicare beneficiaries. The Medicare Modernization Act requires that all DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, Supplies) providers who participate in the Medicare program must be successfully accredited.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Receiving Medicare accreditation is a significant step for Regenesis as we expand the availability of Provant to more Medicare and Medicaid patients," said Virginia Rybski, Acting President of Regenesis. "Our organization's core values parallel Medicare's accreditation quality standards for adhering to ethical business procedures. To earn Exemplary Provider certification, we demonstrated outstanding healthcare delivery practices and compliance to safety, honesty, and compassionate care for our patients and service to clinicians and administrators."

Regenesis' core values include: having a pioneering spirit in the development of new regenerative medical products, striving for excellence in all business aspects, having respect for all people, living and working as a family unified in a common goal, applying integrity in our decision making processes, having compassion for all people, especially our patients, and dedication to improving the lives of all whom we encounter.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact:

Regenesis Biomedical, Inc.

Media: Scott Robey, VP Marketing, robey@regenesisbiomedical.com

Clinicians: Rick Isenberg, MD, VP Clinical Affairs,

isenberg@regenesisbiomedical.com

Investors: Virginia Rybski, Acting President,

rybski@regenesisbiomedical.com

http://www.regenesisbiomedical.com

480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
11. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):